| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 26,885 | 17,328 | 8,149 | - |
| Manufacturing cost of sales | 7,520 | 5,012 | 2,528 | - |
| Profit share and royalties in cost of sales | 1,541 | 967 | 440 | - |
| Research and development | 5,130 | 3,230 | 1,486 | - |
| Sales and marketing | 3,300 | 2,203 | 1,066 | - |
| General and administrative | 1,798 | 1,175 | 621 | - |
| Other segment items | -1,676 | -34 | -573 | - |
| Equity in (income) loss of equity method investments | -19 | -29 | -11 | - |
| Interest income | 311 | 212 | 126 | - |
| Interest expense, net | 2,102 | 1,417 | 723 | - |
| Provision for income taxes | 1,084 | 379 | 243 | - |
| Net income | 6,378 | 3,162 | 1,730 | 3,463 |
| Depreciation, amortization and other | 4,035 | 2,728 | 1,387 | 4,195 |
| Impairment of intangible assets | 1,200 | 800 | 800 | - |
| Stock-based compensation expense | 369 | 242 | 85 | 396 |
| Deferred income taxes | -702 | -672 | -250 | -894 |
| Adjustments for equity method investments | - | - | - | 11 |
| Gains on equity securities | 2,712 | 741 | 1,295 | 717 |
| Other items, net | 101 | 73 | 50 | -1 |
| Trade receivables, net | 1,601 | 1,823 | 1,308 | 32 |
| Inventories | -767 | -527 | -288 | -2,209 |
| Other assets | 690 | 407 | 201 | 638 |
| Accounts payable | 912 | 1,086 | 497 | 544 |
| Accrued income taxes, net | -1,703 | -2,313 | 104 | -1,064 |
| Long-term tax liabilities | 236 | 162 | 70 | -561 |
| Accrued liabilities | -250 | -50 | -874 | -636 |
| Accrued sales incentives and allowance | 2,297 | 1,113 | 486 | 536 |
| Other liabilities | -80 | -70 | -78 | -72 |
| Net cash provided by operating activities | 8,355 | 3,671 | 1,391 | 6,719 |
| Proceeds from sales of marketable securities | - | - | - | 0 |
| Proceeds from maturities of marketable securities | - | - | - | 0 |
| Purchases of property, plant and equipment | 1,216 | 780 | 411 | 725 |
| Other | 34 | 56 | 36 | -81 |
| Net cash used in investing activities | -1,250 | -836 | -447 | -644 |
| Net proceeds from issuance of debt | - | - | - | 0 |
| Extinguishment of debt | 683 | 602 | 301 | 659 |
| Repayment of debt | 5,000 | 3,500 | 2,500 | 3,600 |
| Dividends paid | 3,841 | 2,559 | 1,279 | 3,627 |
| Other | -109 | -119 | -27 | -122 |
| Net cash used in financing activities | -9,633 | -6,780 | -4,107 | -8,008 |
| Decrease in cash and cash equivalents | -2,528 | -3,945 | -3,163 | -1,933 |
| Cash and cash equivalents at beginning of period | 11,973 | 11,973 | 11,973 | 10,944 |
| Cash and cash equivalents at end of period | 9,445 | 8,028 | 8,810 | 9,011 |
AMGEN INC (AMGN)
AMGEN INC (AMGN)